Alstoe has introduced Tempora, a chewable spironolactone tablet indicated in the treatment of congestive heart failure arising from mitral valve disease and can be used alone or in conjunction with standard therapies.
Alstoe Animal Health has introduced a chewable, flavoured, spironolactone tablet for dogs called Tempora. This is indicated in the treatment of congestive heart failure (CHF) arising from mitral valve disease and can be used alone or in conjunction with standard therapies.
It is estimated that degenerative mitral valve disease is the underlying cause in 75% of dogs with CHF.
Spironolactone shows clear benefits in treating mxyomatous mitral valve disease in dogs. Acting as an aldosterone receptor antagonist it counteracts the negative consequences of aldosterone production such as myocardial fibrosis and myocardial and vascular remodelling.
Available in 10mg, 50mg and 100mg tablets, Tempora’s shaped two- and four-way break tablets and effective flavouring technology not only facilitate ease of use, but provide confidence in enhanced compliance.
These benefits when combined with excellent affordability provide optimal value to clients, Alstoe claims.
In addition to offering lunchtime practise seminars Alstoe has designed a Sleep Respiratory Rate (SRR) chart to assist veterinary professionals with ongoing monitoring of their canine patients condition and response to treatment.
The use of this can enhance owner compliance and participation in the therapeutic plan. The charts are available in pads (direct from Alstoe) or as a printable download.